AQST - Company ID 0001398733
The table below shows Aquestive Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$14.81M | -$23.40M | -$10.38M | $8.82M | -$14.48M | -$14.10M |
| Capital expenditure | $52.00K | $135.00K | $29.00K | $2.00K | $104.00K | $103.00K |
| Investing cash flow | -$52.00K | -$135.00K | -$29.00K | -$2.00K | -$104.00K | -$103.00K |
| Dividends paid | - | - | - |
Aquestive Therapeutics, Inc. reported operating cash flow of -$52.43M for fiscal year 2025. That is down 46.6% from -$35.76M in fiscal 2024. Over the 9 fiscal years shown, operating cash flow declined from $5.82M (FY 2017) to -$52.43M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $4.42M | $20.65M | $81.74M | -$9.21M | $1.30M | $9.89M |